Simple Summary KRAS is the most frequently mutated oncogene in non-small cell lung
cancers (NSCLC), with a frequency around 30%, and among them KRAS G12C mutation …

Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in
cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins …

Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten
rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS …

Although KRAS-activating mutations represent the most common oncogenic driver in non-
small cell lung cancer (NSCLC), various attempts to inhibit KRAS failed in the past decade …

Purpose The most frequent mutation in advanced non-small–cell lung cancer (NSCLC),
Kirsten rat-sarcoma viral oncogene (KRAS) is found in 20–25% of these patients' tumors …

KRAS is the most frequently mutated oncogene identified in human cancers. Despite the
numerous efforts to develop effective specific inhibitors against KRAS, this molecule has …

Activating mutations in RAS family proteins are found in~ 25% of all human cancers.
Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten …

Background KRAS mutation is a common driver of NSCLC, and there is a high proportion of
lung cancer patients with KRAS G12C and G12D mutation. KRAS was previously …

KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-
small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct …

Simple Summary RAS mutation is the most frequent oncogenic alteration in human cancers
and KRAS is the most frequently mutated, notably in non-small cell lung carcinomas …